首页> 外文OA文献 >Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammation
【2h】

Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammation

机译:基于急性和慢性炎症的分子特征的系统性红斑狼疮治疗和管理的当前和新兴策略

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Lupus is a chronic, systemic inflammatory condition in which eicosanoids, cytokines, nitric oxide (NO), a deranged immune system, and genetics play a significant role. Our studies revealed that an imbalance in the pro- and antioxidants and NO and an alteration in the metabolism of essential fatty acids exist in lupus. The current strategy of management includes administration of nonsteroidal anti-inflammatory drugs such as hydroxychloroquine and immunosuppressive drugs such as corticosteroids. Investigational drugs include the following: 1) belimumab, a fully human monoclonal antibody that specifically recognizes and inhibits the biological activity of B-lymphocyte stimulator, also known as B-cell-activation factor of the TNF family; 2) stem cell transplantation; 3) rituximab, a chimeric monoclonal antibody against CD20, which is primarily found on the surface of B-cells and can therefore destroy B-cells; and 4) IL-27, which has potent anti-inflammatory actions. Our studies showed that a regimen of corticosteroids and cyclophosphamide, and methods designed to enhance endothelial NO synthesis and augment antioxidant defenses, led to induction of long-lasting remission of the disease. These results suggest that methods designed to modulate molecular signatures of the disease process and suppress inflammation could be of significant benefit in lupus. Some of these strategies could be vagal nerve stimulation, glucose–insulin infusion, and administration of lipoxins, resolvins, protectins, and nitrolipids by themselves or their stable synthetic analogs that are known to suppress inflammation and help in the resolution and healing of the inflammation-induced damage. These strategies are likely to be useful not only in lupus but also in other conditions, such as rheumatoid arthritis, scleroderma, ischemia-reperfusion injury to the myocardium, ischemic heart disease, and sepsis.
机译:狼疮是一种慢性全身性炎症,其中类花生酸,细胞因子,一氧化氮(NO),免疫系统紊乱和遗传起重要作用。我们的研究表明,狼疮中存在前体和抗氧化剂以及NO的不平衡以及必需脂肪酸代谢的改变。当前的管理策略包括非甾体抗炎药(如羟氯喹)和免疫抑制药(如皮质类固醇)的给药。研究药物包括:1)贝利木单抗,一种完全人源的单克隆抗体,可特异性识别并抑制B淋巴细胞刺激物的生物活性,也被称为TNF家族的B细胞激活因子。 2)干细胞移植; 3)利妥昔单抗,一种针对CD20的嵌合单克隆抗体,主要存在于B细胞表面,因此可以破坏B细胞。 4)IL-27,具有有效的抗炎作用。我们的研究表明,皮质类固醇和环磷酰胺的治疗方案以及旨在增强内皮一氧化氮合成和增强抗氧化剂防御能力的方法,可导致该病的长期缓解。这些结果表明,设计用于调节疾病过程的分子标记和抑制炎症的方法可能对狼疮具有显着的益处。其中一些策略可能是迷走神经刺激,葡萄糖-胰岛素输注,以及脂蛋白,分辨素,保护素和硝基脂质的本身或其稳定的合成类似物的给药,这些类似物可抑制炎症并有助于炎症的解决和治愈,诱发的损害。这些策略不仅可能在狼疮中有用,而且在其他情况下也可能有用,例如类风湿性关节炎,硬皮病,心肌缺血再灌注损伤,缺血性心脏病和败血症。

著录项

  • 作者

    Das, Undurti N;

  • 作者单位
  • 年度 2010
  • 总页数
  • 原文格式 PDF
  • 正文语种 {"code":"en","name":"English","id":9}
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号